CTOR

Vorhandelsmarkt: 1.63 -0.02 -1.21%

Citius Oncology Inc (CTOR)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Citius Oncology Inc Stock (CTOR) Company Profile

Citius Oncology Inc

Healthcare (1161)

(908) 967-6677

11 COMMERCE DRIVE, CRANFORD

Nächster Verdiensttermin

Neueste SEC-Einreichungen

CTOR's Discussions on Twitter

Vergleichen Sie CTOR mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CTOR Citius Oncology Inc	1.65	110.19M	0	0	0	0.00
ZTS Zoetis Inc	151.19	68.05B	9.29B	2.52B	2.28B	5.57
TAK Takeda Pharmaceutical Co Adr	14.55	46.58B	30.08B	710.16M	4.45B	0.2182
HLN Haleon Plc Adr	9.65	43.71B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	16.29	18.40B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	297.89	13.23B	2.99B	1.21B	1.13B	25.06

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-11-27	Eingeleitet	Maxim Group	Buy

Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten

Finanzdaten der Citius Oncology Inc-Aktie (CTOR)

Es liegen keine Finanzdaten für Citius Oncology Inc (CTOR) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Citius Oncology Inc (CTOR)

Citius Oncology Inc Stock (CTOR) Company Profile

Vergleichen Sie CTOR mit anderen Aktien

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten

Is Citius Oncology Inc. a good long term investmentTriple-digit profit margins - Autocar Professional

Citius Oncology Inc. Stock Analysis and ForecastFree Stock Market Query - jammulinksnews.com

What analysts say about Citius Oncology Inc. stockFree Wealth Management Insights - jammulinksnews.com

What drives Citius Oncology Inc. stock pricePowerful profit generation - Autocar Professional

Citius Oncology Announces Closing of $9.0 Million Public Offering - Eastern Progress

Citius Oncology shares rise 1.31% after-hours after closing a $9.0 million public offering. - AInvest

Should I buy Citius Oncology Inc. stock before earningsShort Term High Return Strategy - Newser

Citius Oncology Completes $9M Public Offering - TipRanks

Citius Oncology launches $15M equity and warrant offering; shares down - MSN

Citius Oncology closes $9 million public offering to support LYMPHIR - Investing.com Australia

Citius Oncology closes $9 million public offering to support LYMPHIR By Investing.com - Investing.com India

Citius Oncology Raises $9M in Public Offering for LYMPHIR Commercialization - AInvest

Citius Oncology Announces Closing Of $9.0 Million Public Offering - Barchart.com

Citius Oncology Announces Pricing Of $9M "Reasonable Best-Efforts" Public Offering Of 6,818,182 Shares Of Common Stock And Warrants To Purchase Shares Of Common Stock At A Public Offering Price Of $1.32 Per Share - 富途牛牛

Citius Pharmaceuticals shares fall 1.34% after-hours following Citius Oncology's public offering. - AInvest

Citius Oncology’s Chances: Time to Invest? - StocksToTrade

Citius Oncology Announces Pricing of $9.0 Million Public Offering - Finansavisen

Citius Oncology Soars 35.06% on Distribution Deal - AInvest

Citius Oncology Soars 12.34% on Expanded Lymphir Distribution - AInvest

Citius Oncology stock rises after expanding LYMPHIR distribution network - Investing.com

What makes Citius Oncology Inc. stock price move sharplySecure Your Capital Strategy - Newser

Why Citius Oncology Inc. stock attracts strong analyst attentionEarly Breakout Tracker - Newser

Cencora (COR) Partners With Citius Oncology For Immunotherapy Distribution Expansion - simplywall.st

Citius Oncology Shares Climb Following Expansion of LYMPHIR Distribution Network - MSN

Citius Oncology (CTOR): Is LYMPHIR's Launch Priced for Success? - AInvest

Citius Oncology: Is A Lymphir Launch Coming Too Late? - Seeking Alpha

Citius Pharmaceuticals (CTXR) Surges on New Distribution Deal - GuruFocus

Citius Oncology stock rises after expanding LYMPHIR distribution network By Investing.com - Investing.com South Africa

How Citius Oncology Inc. stock performs during market volatilityLow Risk Entry Points - Newser

Citius Oncology Expands Lymphir Distribution With Cencora - MarketScreener

Cencora distribution deal boosts Citius shares - MSN

Citius Oncology expands distribution network for LYMPHIR with Cencora - Investing.com Australia

Citius Oncology expands distribution network for LYMPHIR with Cencora By Investing.com - Investing.com India

Citius stock gains on Cencora distribution deal (CTXR:NASDAQ) - Seeking Alpha

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora - Finansavisen

Citius Oncology shares rise 4.64% after-hours despite plans for stock offering. - AInvest

CTOR Crashes 34%—Is This the Breaking Point for Citius Oncology? - AInvest

Finanzdaten der Citius Oncology Inc-Aktie (CTOR)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie CTOR